Literature DB >> 7734417

CD38 expression on mouse T cells: CD38 defines functionally distinct subsets of alpha beta TCR+CD4-CD8- thymocytes.

A G Bean1, D I Godfrey, W G Ferlin, L Santos-Argumedo, M E Parkhouse, M C Howard, A Zlotnik.   

Abstract

We have examined CD38 expression on mouse lymphocytes using the rat mAb NIM-R5 and demonstrate that CD38 expression is restricted to approximately 8% of thymocytes. Although CD38 is absent from the majority of CD4+CD8- and CD4-CD8+ T cells, we detected a strong correlation between CD38 expression and alpha beta+CD4-CD8- T cells in the thymus, with nearly 80% of alpha beta TCR+CD4-CD8- thymocytes being CD38+. Using heat stable antigen (HSA) and CD38, we divided alpha beta+CD4-CD8- thymocytes into four subsets: HSA+CD38-, HSA-CD38hi, HSA-CD38low and HSA-CD38-. Two established characteristics of alpha beta TCR+CD4-CD8- cells, bias towards V beta 8.2 TCR expression and high levels of IL-4 production, were used to establish a possible relationship between the above thymocyte subsets. Our present data show that the HSA+CD38- subset is not biased towards V beta 8.2 TCR expression whereas the HSA-CD38- subset does show this bias (approximately 47%). Neither of these subsets make IL-4 upon CD3 mediated stimulation. In contrast, the CD38+ subsets are heavily biased toward V beta 8.2 expression and produce large amounts of IL-4 upon stimulation, particularly the CD38low cells. Taken together, these data suggest that these four subsets represent various stages of a possible differentiation pathway for alpha beta TCR+CD4-CD8- cells, with the HSA+CD38- subset being the most immature while the HSA-CD38low subset is the most functionally mature. These characteristics support the view that alpha beta TCR+CD4-CD8- T cells represent an independent lineage with a distinct, but as yet obscure, role in immunity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7734417     DOI: 10.1093/intimm/7.2.213

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

1.  The expression of molecule CD28 and CD38 on CD4⁺/CD8⁺ T lymphocytes in thymus and spleen elicited by Schistosoma japonicum infection in mice model.

Authors:  Na Li; Peng-yu Ji; Lan-gui Song; Jun-xia Lei; Zhi-yue Lv; Zhong-dao Wu; Xiao Shao; Xi Sun
Journal:  Parasitol Res       Date:  2015-05-24       Impact factor: 2.289

2.  Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.

Authors:  Esther Drent; Richard W J Groen; Willy A Noort; Maria Themeli; Jeroen J Lammerts van Bueren; Paul W H I Parren; Jürgen Kuball; Zsolt Sebestyen; Huipin Yuan; Joost de Bruijn; Niels W C J van de Donk; Anton C M Martens; Henk M Lokhorst; Tuna Mutis
Journal:  Haematologica       Date:  2016-02-08       Impact factor: 9.941

3.  A role for CD45RBlow CD38+ T cells and costimulatory pathways of T-cell activation in protection of non-obese diabetic (NOD) mice from diabetes.

Authors:  T C Martins; A P Aguas
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

4.  Residual Bone Marrow T & NK-Cells at Diagnosis in Pediatric Pre-B-ALL: A Case-Control Study.

Authors:  Dalia Mahmoud Eldewi; Hanan A El-Hagrasy; Rasha Mahmoud Gouda; Mohammed Abd El Malik Hassan; Shimaa Moustafa Kamel; Naglaa F Abd El Haliem; Haneya A A Anani
Journal:  Int J Gen Med       Date:  2022-08-07

5.  Ectonucleotidase CD38 demarcates regulatory, memory-like CD8+ T cells with IFN-γ-mediated suppressor activities.

Authors:  Rajia Bahri; Annalena Bollinger; Thomas Bollinger; Zane Orinska; Silvia Bulfone-Paus
Journal:  PLoS One       Date:  2012-09-17       Impact factor: 3.240

Review 6.  CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity.

Authors:  Zayda L Piedra-Quintero; Zachary Wilson; Porfirio Nava; Mireia Guerau-de-Arellano
Journal:  Front Immunol       Date:  2020-11-30       Impact factor: 7.561

7.  CD38 Defines a Subset of B Cells in Rainbow Trout Kidney With High IgM Secreting Capacities.

Authors:  Diana Martín; Pedro Perdiguero; Esther Morel; Irene Soleto; J German Herranz-Jusdado; Luis A Ramón; Beatriz Abós; Tiehui Wang; Patricia Díaz-Rosales; Carolina Tafalla
Journal:  Front Immunol       Date:  2021-11-30       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.